Publications

1. Advice - reimburse midazolam nasal spray (Nasolam®) for the treatment of epilepsy

   The National Health Care Institute has advised the Minister for Medical Care to reimburse midazolam nasal spray (Nazolam®) from ...

   Report | 07-06-2024

2. Advice - reimburse avalglucosidase alfa (Nexviadyme®) for the treatment of Pompe disease

   The National Health Care Institute has advised the Minister for Medical Care to reimburse avalglucosidase alfa (Nexviadyme®), ...

   Report | 30-05-2024

3. Advice - reimburse efgartigimod alfa (Vyvgart®) for the treatment of myasthenia gravis

   The National Health Care Institute has advised the Minister for Medical Care to reimburse efgartigimod alfa (Vyvgart®) from the ...

   Report | 29-05-2024

4. Advice - do not reimburse nivolumab-relatlimab (Opdualag®) for the treatment of skin cancer

   The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to not reimburse ...

   Report | 23-05-2024

5. Advice - conditional inclusion of pembrolizumab (Keytruda®) as an additional treatment of breast cancer prior to surgery

   The National Health Care Institute has advised the Minister for Medical Care to reimburse pembrolizumab (Keytruda®) immunotherapy ...

   Report | 23-05-2024

6. Progress report on the conditional inclusion of orphan drugs, conditionals and exceptionals (progress report year 2023)

   At the request of the Minister of Health, Welfare and Sport (VWS), the National Health Care Institute publishes an annual report ...

   Report | 23-05-2024

7. Advice - reimburse relugolix (Orgovyx®) for the treatment of prostate cancer

   The National Health Care Institute has advised the Minister for Medical Care to reimburse relugolix (Orgovyx®) from the basic ...

   Report | 21-05-2024

8. Advice - reimburse selumetinib (Koselugo®) for the treatment of benign tumours in children with neurofibromatosis type 1 (NF1)

   The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to reimburse selumetinib ...

   Report | 25-04-2024

9. Advice - Reimburse lisocabtagene maraleucel (Breyanzi®) for the treatment of lymphoma

   The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to reimburse lisocabtagene ...

   Report | 11-04-2024

10. Advice - Reimburse deucravacitinib (Sotyktu®) for the treatment of moderate-to-severe psoriasis

    The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to reimburse deucravacitinib ...

    Report | 27-03-2024